Evidence map›Paper›PMID 38863515›Full record

ArticleRespirology case reports2024

Autoimmune pulmonary alveolar proteinosis during the treatment of nonspecific interstitial pneumonia complicated by clinically amyopathic dermatomyositis: A case report.

Naoko Arakawa, Yuno Shiota, Fumi Onizawa, Fumi Miyata, Azusa Miyoshi, Tomohiro Akaba, Mayoko Tsuji, Ken Arimura, Osamitsu Yagi, Mitsuko Kondo and 2 more

Abstract readCase Reports
In one paragraph

Article in Respirology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Naoko ArakawaDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Yuno ShiotaDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Fumi OnizawaDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Fumi MiyataDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Azusa MiyoshiDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Tomohiro AkabaDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.ORCID https://orcid.org/0000-0002-0045-1720
Mayoko TsujiDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Ken ArimuraDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Osamitsu YagiDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Mitsuko KondoDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.
Hideki KatsuraDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.ORCID https://orcid.org/0000-0002-9180-7605
Etsuko TagayaDepartment of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 46-year-old male was treated with corticosteroids for nonspecific interstitial pneumonia (NSIP). He was referred to our hospital and admitted for worsening dyspnea and diffuse ground-glass opacity on chest computed tomography (CT) during corticosteroid treatment. Gottron's sign was observed, and the patient was diagnosed with clinically amyopathic dermatomyositis on skin biopsy. We increased the corticosteroid dose and added immunosuppressive agents; however, the opacity on the chest CT worsened. Based on periodic-acid-Schiff-positive granular material in the bronchoalveolar lavage fluid and the presence of anti-GM-CSF antibodies, the patient was diagnosed with autoimmune pulmonary alveolar proteinosis (APAP). The concentration of anti-GM-CSF antibodies in preserved serum was also elevated when the patient was diagnosed with NSIP. Thus, we assumed that NSIP and APAP coexisted, and that APAP manifested during immunosuppressive therapy. When exacerbation is observed during the treatment of interstitial pneumonia with immunosuppressive agents, it is necessary to consider APAP.

Indexed as

autoimmune pulmonary alveolar proteinosisclinically amyopathic dermatomyositisimmunosuppressive therapynonspecific interstitial pneumonia

Identifiers

PMID38863515
PMCPMC11166472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.